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Bone comprises the largest proportion of the human body’s connective tissue mass.  It is 
considered a composite material as its extracellular matrix is made up of mineral, 
collagen, water, non-collagenous proteins, and lipids.  Bone is unique in its physiology 
compared to other connective tissues in that its matrix is mineralized and is constantly 
turned over throughout the life of an individual.  The mineral phase of bone is composed 
of nanocrystalline hydroxylapatite [(CA10(PO4)6(OH)2] with various substitutions of 
carbonate, magnesium, acid phosphate, and other trace elements which are dependent on 
the environmental and dietary factors of a particular individual.  The functions of the 
mineral in bone are to strengthen the composite, provide mechanical resistance, and serve 
as a source of calcium, magnesium, and phosphate ions for skeletal homeostasis. (Rosen, 
2013)   
2. Osteoblasts/Osteocytes 
There are three cell types present in bone tissue.  One of these is the bone-forming 
osteoblast.  Osteoblasts originate from mesenchymal stem cells which can also 
differentiate into muscle, chondrocytes, fat, ligament, and tendon.  Bone morphogenetic 
proteins (BMPs) are thought to control the commitment of mesenchymal stem cells to the 




mineralize the extracellular matrix.  The process of mineralization involves osteoblasts 
secreting type I collagen and the enzyme alkaline phosphatase, and depositing of calcium 
and phosphate from the blood to bond with osteoid.  (Karsenty & Wagner, 2002) 
One fate of an osteoblast is to become engulfed in the bone mineral and become an 
osteocyte which is a terminally differentiated osteoblast.  Osteocytes create a network 
amongst themselves by extending long processes to nearby osteocytes forming a 
canalicular network.    The cell body remains in the lacuna, and the Haversian canals 
provide a vascular supply where nutrients and waste are exchanged. (Bellido, 2014) 
3. Osteoclasts 
Hematopoietic stem cells are able to differentiate into cells of two primary lineages, 
lymphoid and myeloid.  Osteoclasts, the bone cells responsible for resorption,  are 
derived from the myeloid lineage which includes granulocytes, monocytes, 
megakaryocytes, dendritic cells, erythrocytes, and platelets.  These develop from 
progenitors which originate in the bone marrow.  The commitment to a particular lineage 
is controlled by distinct transcription factors followed by differentiation in response to 
specific colony-stimulating factors. (Kawamoto, 2004) Osteoclasts, which are members 
of the monocyte-macrophage family, are multinucleated giant cells. (Suda et al., 1999) 
Bone marrow macrophages are the physiological osteoclast precursor.  (Teitelbaum, 
2000)  In order for osteoclastogenesis to occur, two key cytokines are essential.  One is 
receptor activator of nuclear factor-κB ligand (RANKL) and the other is macrophage-
colony stimulating factor (M-CSF).  M-CSF has been shown to promote proliferation and 
prevent apoptosis of osteoclast precursors. (Lee & States, 2006)  RANKL stimulates 




Together, M-CSF and RANKL induce the expression of genes that characterize the 
osteoclast lineage, including but not limited to c-Fos, Nfatc1, Dc-stamp, Acp5 and 
Cathepsin K. (Boyle, Simonet, & Lacey, 2003)  The role of these genes in regulating 
osteoclast differentiation is discussed in the following sections.    
3.1 Osteoclast Transcription Factors 
c-Fos 
One of the key regulators of osteoclast lineage determination and bone remodeling is the 
c-Fos oncoprotein.  It is a component of the activator protein 1 (AP-1) transcription factor 
complex which is involved in regulating cell growth and proliferation, cellular 
differentiation, and apoptosis.  c-Fos is active early in the osteoclast differentiation 
process.  As evidence of their role in osteoclast differentiation, it was shown that 
hematopoietic cells lacking c-Fos are unable to differentiate into functional osteoclasts in 
vivo.  Mice with a conditional knockout of c-Fos do not have differentiated, 




Nuclear factor of activated T-cells (NFATc1) is known as the master regulator of 
osteoclast differentiation.  NFATc1 has been shown to regulate genes necessary for 
osteoclast differentiation and resorption. (Song et al., 2009)  The presence of RANKL 
stimulation can induce the expression of NFATc1 the nuclear factor-kappa B (NF-κB) 




was shown that embryonic stem cells deficient in NFATc1 fail to differentiate into 
osteoclasts in response to RANKL stimulation.  Likewise, ectopic activation of NFATc1 
in the absence of RANKL stimulation causes osteoclast precursors to undergo 
differentiation.  Thus, NFATc1 acts as a master switch for regulation of osteoclast 
differentiation and functions downstream of RANKL in the differentiation process. 
(Takayanagi et al., 2002) 
 
Dc-stamp 
The fusion of multiple mononuclear osteoclasts into larger multinuclear cell is a key step 
in the differentiation and function of these cells.  One of the primary genes involved in 
the fusion of osteoclasts is dendritic cell-seven transmembrane protein (DC-STAMP).  
This transmembrane protein is highly expressed in osteoclasts but not in macrophages, 
indicating its key role in the osteoclast lineage.  DC-STAMP is expressed on the cell 
surface and is critical for cell-cell fusion.  DC-STAMP is expressed midway through the 
differentiation process.  (Xing, Xiu, & Boyce, 2012)   Experiments have demonstrated 
that despite normal expression of osteoclast markers and cytoskeletal structure, the 
absence of DC-STAMP results in osteoclast cell fusion being completely halted.   (Yagi 









Figure 1: Genes involved in osteoclast differentiation 
 
3.2 Mechanism of Bone Resorption  
As stated earlier under normal physiological conditions, osteoclasts are responsible for 
resorption of bone.  Resorption begins by multinuclear osteoclasts tightly attaching to the 
bone surface by rearrangement of their cytoskeletal proteins to form a sealing zone.  
Within this sealing zone, the cytoplasmic membrane forms a ruffled border which 
increase the surface area available to contact the bone.  Proteolytic enzymes and 
hydrogen and chloride ions are then secreted onto the bone surface. (Seeman, 2009)  
Hydrogen and chloride ions are responsible for dissolution of the mineralized 
hydroxyapatite matrix while the protease involved in collagen digestion is cathepsin K.  
The importance of cathepsin K was demonstrated by RANKL promoting its expression 
and by knockout mice for the gene displaying significant osteopetrosis.  (Zaidi, Blair, 
Moonga, Abe, & Huang, 2003)  The sealing zone allows for the degradation of the 
mineralized matrix while neighboring cells are simultaneously protected.  (Boyce & 




embedded in the bone matrix are released, and these growth factors recruit osteoblasts to 
resorption sites as well as stimulate osteoblast activity which is vital to the process of 
homeostatic bone modeling and remodeling. (Charles & Aliprantis, 2014) 
Acp5 
Acp5 is the gene that encodes for tartrate-resistant acid phosphatase (TRAP).  TRAP is an 
enzyme found in postmitotic osteoclast precursors and differentiated, multinucleated 
osteoclasts.  The function of TRAP is to dephosphorylate bone matrix proteins like 
osteopontin and bone sialoprotein and allow osteoclast migration along the ruffled 
border.  (Ek-Rylander, Flores, Wendel, Heinegard, & Andersson, 1994)  TRAP activity is 
localized histochemically over these cells and is thus used as a marker of osteoclasts. 
(Minkin, 1982) 
Ctsk 
Cathepsin K (CTSK) is a protease enzyme which plays a major role in osteoclast-directed 
bone resorption.  It is secreted by osteoclasts into the sealed osteoclast-bone cell interface 
and degrades type I collagen and other matrix proteins.  (Drake, Clarke, Oursler, & 
Khosla, 2017)  This protein is expressed later in the differentiation process.  A mouse 
expressing a global knockout of CTSK leads to decreased bone resorption which results 
in osteopetrosis. (Lotinun et al., 2013) 
3.3 Homeostasis 
Bone homeostasis relies on the proper balance of osteoblast and osteoclast function.  It is 
osteoblasts and/or osteocytes that produce the cytokines M-CSF and RANKL to promote 




remodeling occurs over a period of several weeks in a temporary anatomical structure 
known as a basic multicellular unit.  Within this structure a unique microenvironment is 
generated which facilitates coupling of osteoclast resorption and osteoblast formation.  
This functions to ensure there is minimal net change in bone volume during the 
remodeling process.  (Raggatt & Partridge, 2010)  Bone remodeling can be broken down 
into four distinct phases.  The first phase is the activation phase during which detection of 
an initiation signal takes place.  This signal can come in several forms including direct 
mechanical strain on the bone or hormone action on bone cells in response to systemic 
changes.  Next is the resorption phase in which osteoclasts initiate resorption of the 
organic and mineral components of the bone.  This phase lasts two to four weeks.  Upon 
reaching a certain size of resorption area, the resorption process is terminated by 
apoptosis of the osteoclasts.  The reversal phase prepares the resorbed surface for new 
matrix deposition by recruiting macrophage-like cells to smooth the surface.   Finally, the 
formation phase takes place when osteoblasts lay down new bone.  Throughout this phase 
some osteoblasts will become engulfed in the bone and differentiate into osteocytes and 
remain in the lacunae.  The formation phase can last four to six months until osteoblasts 











Figure 2: Myeloid cell lineage 
 
 
3.4 Bone Morphogenetic Proteins / Signaling 
Bone morphogenetic proteins (BMPs) are multifunctional cytokines belonging to the 
transforming growth factor-beta (TGF-β) superfamily.  They are responsible for 
stimulating angiogenesis and migration, proliferation, and differentiation of mesenchymal 
stem cells into cartilage and bone forming cells.  BMPs are known to operate through 




begins when a signal is transmitted across the plasma membrane by the formation of 
heteromeric complexes of specific type I and type II serine/threonine kinase receptors.  
Following the activation of specific type II receptors, the type I receptor is 
phosphorylated which initiates intracellular signaling.  Consequently, specific Smad 
proteins, R-Smads, are phosphorylated and these activated R-Smads form a complex with 
co-Smad, Smad4.  Once formed, this complex will translocate into the nucleus to direct 
transcription of the DNA into corresponding RNA.  This results in targeted gene 
expression.  (G. Chen, Deng, & Li, 2012) 
The non-canonical pathway is a second mechanism for BMP ligands to activate BMP 
signaling.  It occurs when BMP receptors are not dimerized but binding of BMP ligand to 
BMPR-1A recruits BMPR-2 into a complex.  This signaling complex has been shown to 
initiate non-SMAD pathways or non-canonical signaling pathways such as mitogen 
activating protein kinases or MAPKs. 








Osteoclasts express several BMP receptors that are responsible for detecting and 
activating BMP signals resulting in various effects on osteoclastogenesis.   BMP receptor 
type 1A (BMPR-1A) is activated in the late stages of osteoclast differentiation and is 
involved in regulation of osteoclast and osteoblast coupling.  Conditional deletion of this 
gene in osteoclasts results in increased markers of bone resorption while the conditional 
deletion of this gene in osteoblasts results in increased bone formation. (Okamoto et al., 
2011)  In addition, it was shown that osteoclasts derived from mice having a conditional 
deletion of BMPR-1A in their myeloid cells had a decreased ability to form multinuclear 
TRAP positive cells.  (A. Li et al., 2017) These findings demonstrate the biphasic effect 
of BMPs on osteoclast differentiation.   
Another important receptor in BMP signaling is BMP receptor type 2 (BMPR-2).  
Deletion of this gene in myeloid lineage cells including osteoclasts results in mice that 
are osteopetrotic with an increase in both bone volume and trabeculae due to a decrease 
in osteoclast differentiation and activity.  While these mice had changes in the 
noncanonical (MAPK)l pathway, none were observed in the canonical (SMAD) pathway.  
This suggests that these pathways are utilized at different stages of osteoclast 








3.5 BMPs and Osteoclasts 
It has been demonstrated that osteoclasts express BMP-2 in both early lineage cells (bone 
marrow macrophages) and mature osteoclasts.  (Itoh et al., 2001)  In the early lineage 
cells, BMP-2 can either increase or decrease cell proliferation depending on the 
concentration present.  However, this stimulation by BMP-2 does not alter lineage 
commitment.  It is believed that this variable response to BMP-2 stimulation may be a 
technique of controlling maintenance or cell expansion of early lineage cells. (Bhatia et 
al., 1999) 
A series of published studies from the Mansky/Gopalakrishnan lab at the University of 
Minnesota have led to discoveries which serve as the basis of the research presented in 
this thesis.  Since BMPs exert their physiological activities through transmembrane 
receptors, their signaling is subject to regulation at both the intracellular and extracellular 
levels. (Gazzerro & Canalis, 2006)  Twisted gastrulation (TWSG1) is an example of an 
extracellular proteins involved in regulating BMP signaling.  Extracellular modulation of 
BMP signaling by TWSG1 has been shown to occur because TWSG1 physically interacts 
with cell surface receptors used by BMPs.  This direct antagonism limits the accessibility 
of BMPs to their receptors.  In addition, TWSG1 is one of the major modulators of BMP 
signaling in the extracellular space.  The binding of this secreted protein to BMPs is 
required for its inhibitory effects on osteoclasts.  (Huntley et al., 2015)  Mice deficient for 




osteoclastogenesis.  This phenomenon was due to increased cell fusion, differentiation, 
and function of osteoclasts.  The osteoclasts in the TWSG1 knockout mice were 
significantly larger in size than those in wild-type controls.  Furthermore, the enhanced 
osteoclastogenesis in the TWSG1 knockout mice was reversed with exposure to Noggin, 
a BMP antagonist.  The authors were also able to increase RANKL-mediated 
osteoclastogenesis by treating wild-type osteoclasts with rhBMP-2.  These data suggested 
that the enhanced osteoclastogenesis is a result of the increased BMP signaling. 
(Rodriguez et al., 2009)   
In another study, BMP-2 was found to enhance differentiation of multinucleated 
osteoclasts when added to cultures with suboptimal levels of RANKL.  This enhancement 
is not a result of changes in the proliferation or survival of the cells but is accredited to an 
increase in expression of genes involved in osteoclast differentiation and fusion.  When 
osteoclast cultures are treated with BMP-2, expression of RANKL was not significantly 
altered indicating the enhancement of osteoclastogenesis is not mediated through 
increased RANKL expression.  In the absence of RANKL, the addition of BMP-2 did not 
induce osteoclast formation, confirming that BMP signaling is not adequate to induce 
osteoclast differentiation.  Osteoclasts express BMP-2 receptors and the differentiation of 
osteoclasts is promoted by an autocrine signaling mechanism. (Jensen et al., 2010) 
The next publication aimed to overexpress TWSG1 in osteoclasts in order to inhibit 
osteoclast activity.  Overexpression of this gene, which is an inhibitor of BMP-2 
signaling, led to a decreased size and number of TRAP-positive osteoclasts, expression of 
osteoclast genes, and resorption ability.  The authors also demonstrated that by adding 




was able to be rescued.  They were also able to restore the size of enhanced osteoclasts 
found in TWSG1 deficient mice by infecting them with TWSG1 via an adenovirus.  
Furthermore, the rescue of these osteoclasts was reversed by addition of exogenous 
BMP-2.  These experiments confirmed the inhibitory role of TWSG1 in osteoclast 
differentiation by disrupting BMP signaling. (Pham et al., 2010) 
The final study from the lab investigated the role of BMP signaling in osteoclastogenesis 
by eliminating BMP receptor 2 using a conditional knockout.  As stated above in the 
BMP receptor section, a significant decrease in both size and number of multinucleated 
osteoclasts was found in the BMP receptor 2 knockout mice compared to the wild type 
controls.  Bone marrow macrophages, a precursor cell of osteoclasts, are severely 
inhibited in their ability to differentiate into mature multinucleated osteoclasts even in the 
present of M-CSF and RANKL when their BMP receptor 2 is knocked out.  The skeletal 
phenotype of these mice was also altered to have increased bone mass due to the reduced 
bone resorption. (Broege et al., 2013) 
Indirect Effect of BMPs on Osteoclasts 
The above research has shown that BMPs can directly regulate osteoclast 
differentiation.  However, earlier studies demonstrated that BMPs regulate osteoclast 
differentiation indirectly through actions on chondrocytes, osteoblasts, and 
osteocytes.  Starting in 1995, one group demonstrated that cultures of rat bone marrow 
cells treated with osteogenic protein-1 (OP-1) enhanced the ability of vitamin D3 to 
induce formation of TRAP positive osteoclasts in vitro.  (Hentunen et al., 1995)  Both 
murine and chicken chrondrocytes have been shown to express RANKL RNA and 




protein expression from chrondrocytes may act to regulate osteoclast differentiation at 
growth plates in order to remove calcified matrix through BMP induction.  (Usui et al., 
2008)  Another study demonstrated that BMP-2 would stimulate mature osteoclasts in the 
presence but not absence of stromal cells, suggesting that BMP-2 stimulates bone 
resorption by osteoclasts indirectly through stromal cells.  (Kanatani et al., 1995)  Further 
evidence of the involvement of stromal cells was shown by studies that demonstrate 
BMP-2 stimulating bone resorption by osteoclasts through the modulation of RANKL 
RNA expression.  (Itoh et al., 2001)  Other groups have demonstrated that BMP2 can 
modulate the expression of osteoprotegerin (OPG) by osteoblasts and thereby regulate 
osteoclast differentiation. (Kamiya et al., 2016)  Inflammatory conditions may also be 
affected by BMP-2.  When BMP-2 and IL-1  are present in combination, the expression 
of RANKL RNA by osteoblasts is upregulated.  This indirectly enhances osteoclast 
differentiation and may enhance bone resorption during these inflammatory states. 
(Koide et al., 1999)   
Analysis in a mouse model with deletion of Bmpr1a in osteoblasts demonstrates an 
increase in bone mass due to disruption in the ratio of RANKL to OPG resulting in a 
decrease in osteoclast differentiation and activity.  (Shi, Zhang, Louie, Mishina, & Sun, 
2016)  Until more recently the critical role of osteocytes in regulating skeletal 
development were not well understood.  In a mouse model using Dmp1-Cre to 
disrupt Bmpr1a in osteocytes, the authors determined that similar to the mice null 
for Bmpr1a in osteoblasts, the expression of OPG bone RNA was increased and RANKL 




activity.  (Kamiya et al., 2008)   All this data collectively suggests that BMPs can act on 
other cells of the skeleton and indirectly regulate osteoclast differentiation and activity.     
 
 
3.5 Development of Recombinant BMPs 
The first coding sequences for bone morphogenetic protein family members were cloned 
and expressed in the late 1980s.  The identification and isolation of BMPs in bone matrix 
was difficult to obtain due to the proteins being tightly bound to components of the 
extracellular matrix.  Recombinant technologies allowed BMPs to be created for 
therapeutic use.  (Rao, Ugale, & Warad, 2013)   Molecular cloning of their cDNA and 
their expression in Chinese hamster ovary cells allowed the recombinant proteins to be 
obtained in large quantities for preclinical and clinical evaluation and therapeutic use. 
(Carreira et al., 2014)  While at least twenty types of BMPs have been identified in 
humans, only BMP-2 and BMP-7 have been approved by the FDA for therapeutic use in 
medicine.  BMP-7 is typically used in cases of non-union fractures and may be combined 
with autologous bone grafting or used alone. (Gautschi, Frey, & Zellweger, 2007) For 
surgeons who perform bone grafting procedures, these proteins offer a commercially 
available osteoinductive autograft replacement.  The appeal is to avoid having to harvest 
autogenous bone from a second surgical site and the associated complications which 
made the identification and development of rhBMP-2 a significant advancement in the 








Some of the most prevalent conditions of the oral cavity are plaque-induced periodontal 
diseases.  Gingivitis, the more mild and reversible form of periodontal disease, affects 50-
90% of adults in the United States.  (Y. Li et al., 2010)  Periodontitis, the more 
destructive and irreversible form of periodontal disease, has been estimated to affect 47% 
of the adult population in the United States.  (Eke, Dye, Wei, Thornton-Evans, & Genco, 
2012)  The vast prevalence and widespread health and economic burden that this disease 
process poses makes the research and advancement of knowledge in the field valuable to 
millions of individuals. 
Etiology 
Periodontitis is a chronic inflammatory disease which results from the interaction 
between periodontal pathogens and the susceptible host’s immune response.  The 
presence of certain microbes and their by-products elicit an inflammatory response in the 
surrounding periodontal tissues. (Offenbacher, 1996)  While protective in nature, this 
host response can eventually result in local tissue destruction if either hypo- or hyper-
responsiveness of the system occurs.  The primary determinants of the individual host 
response are both genetic and environmental.  (Preshaw, Seymour, & Heasman, 2004)  
Ultimately, periodontitis leads to destruction of alveolar bone, periodontal ligament and 






Periodontal Tissue Destruction by the Host Immune Response 
The host immune response and its interaction with the periodontal bacteria present results 
in various cytokines and chemokines being released which play a role in 
osteoclastogenesis.  Rather than a select few microorganisms being thought of as the 
main pathogens and initiators of periodontal disease, a newer model of pathogenesis has 
been developed.  According to this model termed polymicrobial synergy and dysbiosis, 
periodontitis is initiated by a synergistic and dysbiotic microbial community.  Microbes 
present in the subgingival environment of the periodontitis lesion have various gene 
combinations and virulence factors that enable them to disrupt or evade immune 
surveillance by the human host by fulfilling distinct roles.  The result of this immune 
subversion is a dysbiotic microbial community which disrupts the homeostasis of the 
periodontal tissue microenvironment through various virulence factors including co-
adhesion, production of toxic proteolytic enzymes, and proinflammatory ligands.  
(Hajishengallis & Lamont, 2012)  Together, the dysbiotic microflora are able to sustain a 
proinflammatory state which elicits the host response, eventually resulting in tissue 
destruction if left unresolved.  The breakdown of the tissue creates products that serve the 
nutritional needs of the community and allow further growth of the virulent organisms. 
(Gaffen & Hajishengallis, 2008)   
The direct modulators of osteoclast in periodontitis are RANKL, tumor necrosis factor 
alpha (TNF-α), and interleukin 1 (IL-1).  In addition, bacteria involved in the 
pathogenesis of the disease may produce various forms of LPS and TLR activating 
ligands that can directly stimulate osteoclastogenesis.  (Novack & Mbalaviele, 2016)  




microbes and play a role in signaling the activation of osteoclast differentiation.  
(Jimenez-Dalmaroni, Gerswhin, & Adamopoulos, 2016)  TNF-α and IL-1 are pro-
inflammatory cytokines which participate in the immune response by recruitment and 
activation of adaptive immune cells.  (Ebersole & Cappelli, 2000)  RANKL, which is 
necessary for the complete differentiation of osteoclast precursor cells, is expressed 
primarily by activated B and T cells in the periodontal lesion.  The increased source of 
RANKL plays a primary role in the enhancement of the bone resorption process in 
periodontal disease.  (B. Chen et al., 2014)   
 
 
Applications of Bone Morphogenetic Proteins in Periodontology 
Clinical Applications 
There is currently only one Food and Drug Administration (FDA) approved product for 
the use in oral and maxillofacial surgery and dental regeneration which contains bone 
morphogenetic proteins.  INFUSE® Bone Graft is an alternative to autogenous bone 
grafting and consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) 
placed on a resorbable collagen sponge.  It is indicated for use in sinus augmentation and 
localized alveolar ridge augmentations for defects associated with extraction sockets.  
Clinical research in oral and maxillofacial uses of INFUSE® have demonstrated that at a 
concentration of 1.5mg/cc, significant bone formation is induced which is biologically 
similar to native bone and is suitable for dental implant placement.  Osseointegration of 




successful.  (McKay, Peckham, & Badura, 2007)  In sinus augmentation, rhBMP-2 was 
found to increase the overall mean vertical height of the available bone by 8.51mm 
without any serious immunologic or adverse effects. (Boyne et al., 1997)  Alveolar ridge 
preservation after tooth extraction and localized alveolar ridge augmentation have also 
been demonstrated to be safe and feasible treatments with the use of rhBMP-2.  (Howell 
et al., 1997)   
Mechanism of Action 
The mechanism of action of rhBMP-2 is through osteoinduction.  It stimulates the 
recruitment and differentiation of bone-forming cells which induce new bone formation 
or aid in the healing of existing bone.  Once rhBMP-2 is implanted, the migration of 
mesenchymal stem cells to the site of implantation occurs.  The rhBMP-2 and the 
absorbable collagen sponge provide an environment where the stem cells are able to 
multiply.  (Wilke, Traub, Kienapfel, & Griss, 2001)  They then differentiate into 
osteoblasts due to the rhBMP-2 binding to specific receptors on the stem cell surface.  
Once differentiated, osteoblasts are able to produce new mineralized tissue which 
replaces the absorbable collagen sponge.  (Puleo, 1997)  Concurrently, angiogenesis is 
taking place.  In response to the local environmental and mechanical forces, the bone is 








Complications and Adverse Events 
While rhBMP-2 does show promise as an alternative to autogenous bone grafting, it is 
not without a potential for adverse side effects and events.  Clinical trials demonstrated 
that the most frequent adverse events associated with INFUSE® are mouth pain (85.0%), 
oral edema (67.5%), facial edema (67.5%), and oral erythema (47.5%).  The significant 
amount of edema present with the use of this product is likely due to the recruitment of 
fluid and cells into the area being treated.  The immune response of the patients in these 
clinical trials were assessed for the presence of antibodies using an enzyme-linked 
immunosorbent assay (ELISA) before and after the use of rhBMP-2.  Of the 184 patients 
tested, 4 of them (2.2%) had a positive antibody response to rhBMP-2.  It is theoretically 
possible that the antibodies made in response to rhBMP-2 could neutralize endogenous 













RATIONALE AND SIGNIFICANCE 
 
At the center of the alveolar bone destruction present in inflammatory, plaque-induced 
periodontitis is enhanced osteoclastogenesis and the subsequent pathologic resorption of 
bone by these osteoclasts.  Advancing the knowledge in the fields of bone biology and 
periodontology are paramount to developing therapies that can help prevent and/or reverse 
periodontal tissue destruction.  Multiple publications from the Mansky/Gopalakrishnan lab 
have established BMPs as important in vivo regulators of osteoclast formation and 
demonstrated that aberrant activation of BMP signaling in osteoclasts promotes bone 
resorption in mice.   (Broege et al., 2013; Jensen et al., 2010; Pham et al., 2010; Rodriguez 
et al., 2009)  This disproportionate bone loss is similar to the pathological bone loss of 
human diseases such as osteoporosis, rheumatoid arthritis, osteolytic cancers, and 
periodontitis.  These disorders which cause osteoclast-mediated bone destruction create a 
serious burden on both patient morbidity and the economic costs associated with treating 
them.  There is a great need for new treatments aimed at osteoclasts.  BMPs have been 
suggested as potential therapeutic targets with the prediction that inhibiting their signaling 
will impair osteoclast formation and reduce bone loss.  Bone formation and bone resorption 
must be precisely balanced in order to sustain normal skeletal homeostasis.  BMPs are 
important positive regulators of bone formation.  The effectiveness of BMPs in promoting 
bone formation has been documented.  However, what is still poorly understood is the 
mechanisms by which BMPs regulate bone resorption through the direct regulation of 
osteoclast differentiation and activity.  The significance of this current study will be to add 




refine current therapies and contribute to improved preventive, therapeutic, and bone 



















MATERIALS AND METHODS 
 
Breeding of Bmp2fl/fl;LysM-Cre   
Bmp2fl/fl mice were obtained from Dr. Stephen Harris, University of Texas-San Antonio 
(Ma & Martin, 2005).  These mice were crossed with B6.129-Lyzstm1(cre)Ifo/J mice 
(LysM-Cre) which expresses CRE recombinase in cells of the myeloid lineage (Jackson 
Labs (Clausen, Burkhardt, Reith, Renkawitz, & Forster, 1999).  The use and care of these 
mice was reviewed and approved by the University of Minnesota Institutional Animal 
Care and Use Committee, IACUC protocol number 1806-36053A.  Mice were euthanized 
by asphyxiation with CO2. 
 
Primary Osteoclasts Cell Culture 
Primary bone marrow macrophages were harvested from the femurs and tibiae of wild-
type or Bmp2fl/fl;LysM-Cre littermates and adherent tissue was removed. Primary bone 
marrow macrophages from the mice were then isolated from the femora and tibiae. The 
ends of the femora and tibiae were cut and the bone marrow was flushed out from the 
inner compartments.  Red blood cells were lysed from the flushed marrow using red cell 
blood lysis buffer (150 mM NH4Cl, 10 mM KHCO3 , 0.1 mM EDTA, ph 7.4). The 
resulting cells were then plated and cultured overnight in 10 cm tissue culture dishes 
(TPP, MidSci) in osteoclast media (phenol red-free alpha-MEM (Gibco) with 5% heat 




400 mM L-Glutamine (Invitrogen), and supplemented with 1% CMG 14-12 (culture 
supernatant containing M-CSF). Cell populations that were non-adherent, including 
osteoclast precursor cells, were then removed and replated in 12-well cell culturing plates 
(TPP, MidSci) at a concentration of 2 x 105 cells/well in osteoclast media supplemented 
with 1% CMG culture supernatant containing M-CSF. Subsequently, every two days, 
cells were refed with 1% CMG plus 10 ng/mL of RANKL (R&D Systems) to initiate 
osteoclastogenesis. 
 
Selecting for Osteoclasts  
This process selects for osteoclast precursors because T-cells and B-cells do not 
recognized M-CSF.  Stromal cells adhere to the plates while the osteoclasts/macrophages 
are floating.  TRAP staining then further distinguishes osteoclasts because they are the 
only TRAP-positive cell present.  Sorting is not necessary because the knockout is 
conditional only in myeloid lineage cells and is not a global knockout.  This is consistent 
with protocols used throughout the literature. 
 
Tartrate Resistant Acid Phosphatase (TRAP) Staining 
After culturing the primary osteoclasts as described above, the cells were fixed with 4% 
paraformaldehyde for 20 minutes. Primary osteoclasts expressing TRAP were stained 
using the Naphthol AS-MX phosphate and Fast Violet LB salt protocol (BD Biosciences 
Technical Bulletin #445).  The composition of this stain included tartrate 5 mg, Naphthol 




acetic acid, 6.8 g sodium acetate trihydrate, 11.5 g sodium tartrate in 1 L water) and 25 
mg Fast Violet LB salt.  Cells that were stained were imaged and photographed using 
bright field light microscopy at 4x magnification. The pictures were analyzed using NIH 
ImageJ to measure the size in area and number of the TRAP positive osteoclasts.  Mean 
cell count and mean average size in micrometers were calculated from the three images 
taken per sample. 
 
RNA Isolation and Real-Time PCR 
RNA was harvested from primary osteoclasts plated in duplicate using TRIZOL Reagent 
(Ambion, Life Technologies) and quantified using UV spectroscopy. cDNA was then 
prepared from 1 ug of purified RNA using iScript cDNA Synthesis Kit (Bio-Rad) as per 
manufacturer’s protocol. Quantitative real-time PCR was performed in duplicate using 
CFX Connect Real-Time PCR system (Bio-Rad). Each reaction contained 10 l iTaq 
Universal Sybr Green Supermix, 8.8 l DEPC water, 500 nM forward and reverse primers, 
and 1 l cDNA for a total of 20 l per reaction. The PCR conditions were as follows: 95°C 
for 3 minute, and 40 cycles of 94°C for 15 seconds, 58°C for 30 seconds, and 72°C for 30 
seconds, followed by melting curve analysis (95°C for 5 seconds, 65°C for 5 seconds, and 
then 65°C to 95°C with 0.5°C increase for 5 seconds). C-fos (Forward) 5’-CCA AGC GGA 
GAC AGA TCA ACT T (Reverse) 5’-TCC AGT TTT TCC TTC TCT TTC AGC 
AGA; Nfatc1 (Forward) 5’ -TCA TCC TGT CCA ACA CCAAA; (Reverse) 5’ -TCA CCC 
TGG TGT TCT TCC TC; Cathepsin K (Forward) 5’-AGG GAA GCA AGC ACT GGA 




CAC CAG TAT TTT CCT GA; (Reverse) 5’ -TGG CAG GAT CCA GTA AAA GG.  
Experimental genes were normalized to Hprt (Forward) 5’-GAG GAG TCC TGT TGA 
TGT TGC CAG and (Reverse) 5’-GGC TGG CCT ATA GGC TCA TAG TGC.  All 
measurements were performed in duplicate and analyzed using the 2 −ΔΔCt method. 
 
Statistical Analysis 
Each experiment for cell count and size was run in triplicate and performed three times.  
Each experiment for gene expression was run in duplicate and performed three times. All 
results are expressed as mean ± standard deviation. Student’s unpaired t-test were used to 
compare data using GraphPad Prism version 8.  A p-value of p < 0.05 indicates 
significance.  Descriptive statistics were used to present the results of the sample’s 
characteristics including mean, standard deviation, range, and difference of means for cell 
count, average cell size, and relative expression of genes. 
Hypothesis testing to determine the probability that a given hypothesis is true using 
statistics consists of four steps.  The first is formulating a null and alternative hypothesis.  
The null hypothesis is that there is no difference between the two groups, or that the 
observations seen are a result of pure chance.  The alternative hypothesis is that the 
observations seen show a real effect.  The second step is identifying a test statistic that 
can be used to assess the truth of the null hypothesis.  The test statistic used in the 
research being presented is the t-value.  The t-value measures the size of the difference 
relative to the variation in the sample data.  More specifically, a 2-sample t-test is being 




control and test groups.  The third step is computing a p-value.  The p-value is the 
probability that a test statistic at least as significant as the one observed would be 
obtained assuming the null hypothesis is true.  The final step is to compare the p-value to 
an acceptable significance value (known as the alpha value or α).  If p ≤ α, then the 
observed effect is considered statistically significant, the null hypothesis is taken as false, 
and the alternative hypothesis is taken as valid. A large p-value provides more evidence 
toward the null hypothesis and a smaller p-value provides stronger evidence against the 
null hypothesis.  
Two types of errors can occur when performing hypothesis testing.  The first is the type I 
error which is the incorrect rejection of the null hypothesis.  When this error is made, the 
statistics reveal a significant difference when there actually is not a significant difference.  
This is also known as a false positive.  The other error that can be made is the type II 
error which is the incorrect retention of a null hypothesis that is false.  When this error is 
made, the statistics reveal no significant difference when there actually is a significant 
difference.  This is also known as a false negative. 
The statistical power of any test of statistical significance is the probability that it will 
reject a false null hypothesis.  In other words, power is the likelihood that a test will 
detect an effect where there is an effect to be detected.  When the statistical power is 
high, the probability of making a type II error goes down.  In this research, a sample size 
of 9 and 18 in two groups will have 80% power to detect an effect size of 1.19 (ratio of 







Osteoclasts null for BMP2 expression are smaller than wildtype osteoclasts 
As presented in the introduction, multiple researchers have demonstrated that BMP 
signaling enhances RANKL stimulated osteoclast differentiation and that osteoclasts 
express BMPs.  (Itoh et al., 2001)  Research from the Mansky lab had demonstrated that 
osteoclasts express Bmp2 mRNA throughout differentiation.  (Jensen et al., 2010)   
However, there has been no in vivo research to date demonstrating the significance of 
BMP2 expression by osteoclasts on the skeleton.  In an attempt to address this research 
question, bone marrow macrophages were cultured in the presence of M-CSF and 
RANKL to generate osteoclast cultures.  Osteoclasts were fixed and stained for TRAP.   
Using the computer program NIH Image J, osteoclast size and number were quantitated.  
Before analysis of size and number of TRAP stained cells, parallel cultures of osteoclasts 
were analyzed by RT-qPCR to verify loss of Bmp2 expression (data not shown).  TRAP 
positive multinucleated osteoclasts were measured on day two, three, and four after 
RANKL stimulation.  Both the total number of cells present and the average size of the 
cells were evaluated.  The data shown are presented in the following graphical 















































































Figure 5: Bone marrow macrophages (BMMs) were flushed from WT or BMP2cKO 
mice.  BMMs were stimulated with M-CSF and RANKL for indicated days.  TRAP 
stained images were quantified for number of TRAP positive cells at 2 days, 3 days or 4 



















Table 1: Cell counts 
Cell 
Count 














18 71.15 24.48 26.67 – 
119.30 
       
Day 3 
WT 








18 50.13 31.31 7.00 – 
87.00 
       
Day 4 
WT 








18 44.41 8.76 28.67 – 
58.33  
 
The results of the cell counts from both the wild type and Bmp2 null osteoclasts for days 
2, 3, and 4 are presented in Table 1.  The sample size for all the wild type groups was 9 
and the sample size for all of the Bmp2 null groups was 18.  In both groups, the mean 
number of cells progressively decreased from day 2 through day 4.  While there were no 
statistically significant differences (p < 0.05) between the two groups at any of the three 
timepoints, there was a trend at day 4 of the wild type cell count being less than the 



















































Figure 6: Bone marrow macrophages (BMMs) were flushed from WT or BMP2cKO 
mice.  BMMs were stimulated with M-CSF and RANKL for indicated days.  TRAP 
stained images were quantified for size of TRAP positive cells at 2 days, 3 days or 4 






















Table 2: Average size 
Average Size 
(micrometers) 
n Mean SD Range Difference 
of Means 
p-value 









Day 2 KO 18 0.0019 0.0004 0.0001 – 
0.0025 
       









Day 3 KO 18 0.0109 0.0046 0.0047 – 
0.0213 
       







Day 4 KO 18 0.0283 0.0162 0.0111 – 
0.0573 
 
The results of the cell size from both the wild type and Bmp2 null groups for days 2, 3, 
and 4 are displayed in Table 2.  As stated for Table 1 and Figure 5, the sample size for all 
the wild type groups was 9 and the sample size for all of the knockout groups was 18.  In 
both groups, the mean cell size progressively increased from day 2 through day 4.  There 
were no statistically significant differences (p < 0.05) between the groups at day 2 or day 
3; however, at day 3 the difference in cell size approached statistical significance 
(p=0.0606) with the wild type cells being larger than the knockout cells.  At day 4, the 
wild type cells had a statistically significant larger mean cell size when compared to the 













































Bmp2 null osteoclasts have no changes in gene expression 
To begin to understand mechanistically how loss of Bmp2 expression leads to a decrease 
in osteoclast size, real time quantitative polymerase chain reaction (RT-qPCR) was used 
to detect and quantify RNA transcripts of four specific genes.  As presented in the 
introduction, the expression of the examined genes are important for osteoclast formation 
and function. 
Figure 7: qRT-PCR comparing expression of c-Fos from WT and BMP2cKO mice after 2, 3 or 4 
days of RANKL treatment.  (Data shown are the mean + SD of three independent experiments in 
which gene expression was measured from three wells of each genotype, with each PCR reaction 



















n Mean SD Range Difference 
of Means 
p-value 






Day 2 KO 12 0.6214 0.5557 0.0409 –  
1.105 
       






Day 3 KO 12 0.5676 0.4870 0.1768 –  
1.5210 
       






Day 4 KO 12 0.1495 0.1495 0.0285 –  
0.2912 
 
The results of the gene expression of c-Fos measured from RT-qPCR from both the wild 
type and knockout groups for days 2, 3, and 4 are displayed in Table 3.  The mean is 
reported as the relative expression of the target gene, c-Fos, to the housekeeping gene, 
Hprt (cFos:HPRT).  The sample size for all the wild type groups was 6 and the sample 
size for all of the Bmp2 null groups was 12.  In both groups, the relative expression of c-
Fos:Hprt decreased from day 2 through day 4.  There were no statistically significant 














































Figure 8: qRT-PCR comparing expression of Ctsk from WT and BMP2cKO mice after 2, 
3 or 4 days of RANKL treatment.  (Data shown are the mean + SD of three independent 
experiments in which gene expression was measured from three wells of each genotype, 
with each PCR reaction performed in duplicate.  Expression of each gene is graphed 























n Mean SD Range Difference 
of Means 
p-value 













       
Day 3 WT 6 68.81 52.36 
 







Day 3 KO 12 67.40 48.13 
 
15.30 –  
144.5 
       















31.89 –  
99.73 
 
The results of the gene expression of Ctsk measured from RT-qPCR from both the wild 
type and Bmp2 null groups for days 2, 3, and 4 are displayed in Table 4.  The mean is 
reported as the relative expression of the target gene, Ctsk, to the housekeeping gene, 
Hprt (Ctsk:Hprt).  The sample size for all the wild type groups was 6 and the sample size 
for all of the knockout groups was 12.  In both groups, the relative expression of 
Ctsk:Hprt increased significantly after day 2.  There were no statistically significant 


















































Figure 9: qRT-PCR comparing expression of Dc-stamp from WT and BMP2cKO mice 
after 2, 3 or 4 days of RANKL treatment.  (Data shown are the mean + SD of three 
independent experiments in which gene expression was measured from three wells of 
each genotype, with each PCR reaction performed in duplicate.  Expression of each gene 























n Mean SD Range Difference 
of Means 
p-value 















0.2658 –  
6.320 
       















0.6507 –  
6.989 
       


















The results of the gene expression of Dc-stamp measured from RT-qPCR from both the 
wild type and knockout groups for days 2, 3, and 4 are displayed in Table 5.  The mean is 
reported as the relative expression of the target gene, Dc-stamp, to the housekeeping 
gene, Hprt (Dc-stamp:Hprt).  The sample size for all the wild type groups was 6 and the 
sample size for all the Bmp2 null groups was 12.  In both groups, the relative expression 
of DC-STAMP:HPRT was the highest on day 3.  There were no statistically significant 
differences (p < 0.05) between the groups at any of the timepoints measured.  
Dc-stamp was about twice as high on day 3 as on days 2 or 4.  The gene Ctsk, responsible 
for producing protease enzymes involved in resorption, is activated later in differentiation 
and evidence of this was seen as the levels of expression were two to three times higher 











































Figure 10: qRT-PCR comparing expression of Nfatc1 from WT and BMP2cKO mice 
after 2, 3 or 4 days of RANKL treatment.  (Data shown are the mean + SD of three 
independent experiments in which gene expression was measured from three wells of 
each genotype, with each PCR reaction performed in duplicate.  Expression of each gene 






















n Mean SD Range Difference 
of Means 
p-value 

















       















0.09706 –  
1.500 
       















0.02547 –  
0.5434 
 
The results of the gene expression of Nfatc1 measured from RT-qPCR from both the wild 
type and Bmp2 null groups for days 2, 3, and 4 are displayed in Table 6.  The mean is 
reported as the relative expression of the target gene, Nfatc1, to the housekeeping gene, 
Hprt (Nfatc1:Hprt).  The sample size for all the wild type groups was 6 and the sample 
size for all of the Bmp2 null groups was 12.  In both groups, the relative expression of 
Nfatc1:Hprt decreased from day 2 through day 4.  There were no statistically significant 








In the present investigation, the first outcome evaluated was the number of cells present 
at each day during the differentiation process.  Determining whether the number of cells 
present affects cell fusion and development of multinucleated osteoclasts was the 
objective of obtaining this information.  While there were no significant differences 
between the Bmp2 knockout and wild-type groups at any of the three timepoints, both 
groups followed a similar trend of decreasing number of cells over time.  This can be 
explained by the normal process of osteoclast differentiation.  Upon stimulation of 
monocytes with RANKL, the monocytes begin to differentiate and fuse forming giant 
multinucleated osteoclast cells.  This process requires four to five days to accomplish and 
then the osteoclasts can be observed in culture for only two to four days before they die 
by apoptosis.  (Akchurin et al., 2008)  Day 2 is right before cell fusion and mean cell 
count of the wild-type group was 83.26 and the knockout group was 71.15.  This 
difference was not statistically significant. (p=0.2892).  It is not expected to see a 
difference in osteoclast size at this timepoint because none of the cells have undergone 
fusion and thus are all still mononuclear monocytes.  At day 3 as the individual cells 
begin to fuse and start forming multinucleated cells, the mean cell count of the wild-type 
group dropped to 54.15 and the knockout group dropped to 50.13.  This difference was 
also not statistically significant (p=0.7260).  The decrease in number of cells in both 
groups is expected because the mononuclear cells are fusing to become multinuclear.  At 
day 4 when the osteoclasts are fully differentiated, the mean cell count dropped to 37.07 
and 44.41 for the wild-type and knockout groups, respectively.  The further decrease in 




continuing to fuse and becoming larger.    While this difference was not statistically 
significant, it did approach the α level (p<0.05) of significance with a p-value of 0.0557.  
This difference correlates well with the average cell size difference found between the 
groups at day 4.  The wild-type cells are significantly larger than the knockout cells, so 
there are fewer of them present in any one microscope image taken.   
The second outcome evaluated was the average size of the osteoclasts at each time period 
measured in area (mm2).  Determining how the presence of BMP-2 affected the fusion 
and size of differentiated multinucleated osteoclasts was the objective of obtaining this 
information.  At day 2, there were no statistically significant differences between the 
average size of the wild-type (0.0018mm2) and knockout (0.0019mm2) groups with a p-
value of p=0.9163.  It is expected that the cell size is unchanged at day 2 because no cell 
fusion has occurred yet, and all of the cells are still mononuclear.  At day 3, the cell-cell 
fusion process has begun in vitro and multinucleated cells begin to form.  The mean size 
of the wild-type cells was 0.0157mm2 and of the knockout cells was 0.0109mm2.  The 
difference of these values approached statistical significance with a p-value of p=0.0606.  
The microscopic images taken and displayed in the findings of this paper show evidence 
of the increased size of the wild-type cells compared to the knockout cells.  At day 4, 
most of the osteoclasts are fully differentiated and fusion has occurred.  There was a 
statistically significant difference between the mean size of the wild-type cells 
(0.00529µm2) and the knockout cells (0.0283µm2) with a p-value of p=0.0134.  Images 
of the cells under brightfield microscopy at 4x magnification reveals cells expressing 




The significant difference in osteoclast size is a noteworthy finding because it confirms 
data generated demonstrating that recombinant BMP2 added to osteoclast cultures 
enhances the size of the osteoclasts.  A related study found an increased number of nuclei 
per cell in murine cells that were deficient for TWSG1, which is a BMP antagonist.  They 
attributed the larger phenotype of the multinucleated osteoclasts to excessive fusion of 
mononuclear progenitors.  Also in line with the results of the present study, they found 
little effect on overall number of TRAP-positive cells.  (Jensen et al., 2010)  Future 
studies may be interested in investigating how the number of nuclei in osteoclasts at 
different points of differentiation is affected by the knockout of the BMP-2 gene.  A 
staining technique that could be used for this purpose is 4′,6-diamidino-2-phenylindole 
(DAPI).  DAPI is a fluorescent stain that can visualize nuclear DNA in both living and 
fixed cells.  (Tarnowski, Spinale, & Nicholson, 1991) 
When looking at gene expression of the four genes investigated between the test and 
control groups at each day, no statistically significant differences were found.  However, 
predictable observations were made in regard to the relative expression of each gene at 
different days.  The trends were similar for both the wild-type and knockout groups.  The 
expression of c-Fos was two to four times greater on days 2 and 3 than on day 4.  This 
comes as no surprise since c-Fos is a transcription factor important to committing cells to 
the osteoclast lineage and is active early on in the differentiation process.  Nfatc1 which 
is also found early in the differentiation process was found to be expressed at levels of 
three to ten times higher on day 2 or 3 than on day 4.  The gene responsible for fusion of 
osteoclasts into larger multinuclear cells is Dc-stamp and is most highly expressed 




relative expression of Dc-stamp as about twice as high on day 3 as on days 2 or 4.  The 
gene Ctsk, responsible for producing protease enzymes involved in resorption, is 
activated later in differentiation and evidence of this was seen as the levels of expression 
were two to three times higher on days 3 and 4 than on day 2.   
There could be several reasons for no significant differences being found between the test 
and control groups for the relative expression of the four selected genes.  The sample size 
is relatively small at only 6 and 12 samples per control and test groups, respectively.  
Increasing the sample size may allow a difference to be detected if it in fact exists.  
Another observation is that the standard deviations are very high in respect to the mean 
values.  In most cases, the standard deviation was at least half of the mean value and in 
some cases the standard deviation even exceeded the mean. 
These four genes were selected to be investigated because they are all known to be 
involved in osteoclast differentiation.  The effect of the presence or absence of BMP-2 
expression on these genes was unknown and is why they were selected for investigation.  
From the current data, it is not possible to state that there is a difference in relative gene 
expression for mice null of BMP-2.  Therefore, the null hypothesis is accepted as true. 
There are numerous other genes involved in this process and it is possible that 
investigating other genes might provide more insight into how BMP-2 affects osteoclast 
differentiation.  In future studies, a wider array of genes could be included to determine 
which are being affected.  One method in which this could be accomplished is RNA 
sequencing (RNA-Seq).  This technique covers a wide range of transcript abundance and 
can identify mRNA transcripts at a single nucleotide resolution.  Advantages of RNA-




differences in gene expression in different groups.  (Pimentel, Bray, Puente, Melsted, & 
Pachter, 2016)  Another technique that could be considered is a DNA microarray.  This 
technique is employed to measure the expression levels of a large number of genes 
simultaneously.  DNA microarrays are also versatile in the fact that they can detect DNA 
or RNA (in the form of cDNA after reverse transcription).  This laboratory method has 
been used successfully in other studies to profile the gene expression of osteoclast 
differentiation already.  (Rho et al., 2002)   
In the present study, the most significant finding was the difference in the average cell 
size between the control and knockout groups.  From this finding, it is evident that 
osteoclast fusion is one of the processes most greatly affected by the absence of BMP-2.  
Future investigations may focus more closely on other genes that are known to be 
involved in the fusion of osteoclasts during differentiation.  Several candidates to explore 
further are triggering receptor expressed on myeloid cells 2 (TREM2), ATPase H+ 
transporting v0 subunit d2 (ATP6v0d2), cellular communication network factor 2 
(CCN2), CD9 molecule (CD9), and macrophage fusion receptor (MFR).  TREM2 
induces fusion of pre-osteoclasts into multinucleated cells and in its absence osteoclast 
development and fusion are impaired.  (Helming et al., 2008)  ATP6v0d2 is a component 
of the ATPase pump and is required for osteoclast fusion under basal conditions.  
Without this gene, it has been shown that the fusion of pre-osteoclasts to mature 
osteoclasts is inhibited.  In addition, bone formation is significantly increased in mice that 
have this gene knocked out because it is found only in osteoclasts and not in osteoblasts.  
(Xing et al., 2012)  CCN2 is a connective tissue growth factor that promotes 




osteoclastogenesis is impaired in cells void of this gene and that they can be rescued by 
the addition of recombinant CCN2.  The combination of recombinant CCN2 and RANKL 
greatly enhances TRAP-positive multinucleated osteoclast cell formation.  (Nishida, 
Emura, Kubota, Lyons, & Takigawa, 2011)  CD9 is a protein of the tetraspanin 
superfamily.  It is implicated in a variety of cell processes which includes fusion.  
Researchers demonstrated that blockage of CD9 by neutralizing antibodies reduces 
osteoclast formation while its over-expression promotes cell fusion.  (Ishii et al., 2006)  
MFR was the first molecule identified to be critical for macrophage fusion.  Its 
interaction with CD47, an integrin-associated protein that binds to the receptor of MFR, 
is involved in cell-cell recognition at the time before cell-cell fusion.  Blockage of this 
pathway results in reduced formation of TRAP-positive multinucleated osteoclasts in 
cultures of murine bone marrow cells.  (Lundberg et al., 2007) 
The maintenance of the skeletal system and the balance between bone formation and 
resorption is a key biological process carried out by all vertebrates.  Regulation of these 
processes are influenced by certain autocrine and paracrine factors like BMPs.  It is 
recognized that BMPs enhance bone formation, but their interactions on osteoclasts and 
bone resorption is not clearly understood.  The results of this study contribute to the 
growing body of evidence that BMP signaling has an influence on the differentiation and 
biologic activity of osteoclasts.  BMP-2 has already been shown to cause both a dose- and 
time-dependent increase in bone resorption by osteoclasts.  It also elevates the mRNA 
expression of carbonic anhydrase II which is a key enzyme for degrading inorganic bone 
matrices.  (Kaneko et al., 2000)  Specific members of the BMP family, one of which is 




positive multinucleated cells.  (Kanatani et al., 1995)  More evidence of the stimulatory 
effects of BMP on osteoclast formation and function was revealed when researchers 
found that BMP-2 may increase bone resorption rather than bone formation if added to an 
inflammatory environment.  They showed that the combination of BMP-2 with IL-1a 
caused an increase in the formation of cyclooxygenase-2 and RANKL mRNA in 
osteoblasts.  The enhancement of these factors in osteoblasts was seen phenotypically as 
an increase in the differentiation of osteoclasts.  (Koide et al., 1999) 
Going forward, this research may be used to better understand the effect BMP-2 has on 
the relationship between bone resorption and bone formation in both osteoclasts and 
osteoblasts.  The data presented here demonstrates that osteoclast fusion and 
differentiation is affected by the absence of BMP-2.  Future research may be aimed at 
determining if addition of exogenous BMP-2 is able to rescue the phenotype of these 
osteoclasts.  In addition, it is unclear from the current research and evidence if the altered 
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